Presentation is loading. Please wait.

Presentation is loading. Please wait.

INTEGRATIVE APPROACHES TO TREATING PROSTATE CANCER AND PROSTATITIS.

Similar presentations


Presentation on theme: "INTEGRATIVE APPROACHES TO TREATING PROSTATE CANCER AND PROSTATITIS."— Presentation transcript:

1 INTEGRATIVE APPROACHES TO TREATING PROSTATE CANCER AND PROSTATITIS

2 Prostate Cancer Patterns of Prostate Cancer Physiological vs. Pathological Maintenance vs. Cure Supplements & Adjuvant Therapy

3 Prostate Cancer General Guidelines Grade of the Disease Stage of the Disease PSA Therapeutic Surgery, Radiation, Hormonal Hormonal Refractory Disease Grade & State of the Person

4 Prostate Cancer-Stages Biopsy Watchful Waiting Local Therapy Hormonal Therapy Androgen Independent Advanced Disease

5 Prostate Cancer Evaluation History: Risk Factors, Family History, Age, Ethnicity Physical Exam - Digital Rectal Exam PSA - Discussion Laboratory Testing

6 History Big Picture Details Flow Timing & Rhythms

7 Physical Exam Traditional Temperature Distribution Excess & Deficiencies Relationships Pulse Diagnosis Tongue Diagnosis

8 Laboratory Testing General Cancer Specific

9 Laboratory Testing - Continued General Circulation Inflammation Hormonal Metabolic Immune Cancer Markers

10 Circulation & Inflammation LP(a) CRP Fibrinogen Galectin-3 Homocysteine PT/PTT IL-8, IL-6

11 Cancer Markers The more you test, the better

12 Laboratory Testing Prostate Cancer CBC Comp Metabolic Panel Lipid Panel Lipo (a) PSA Free/Total PCA-3 PAP Fibrinogen Testosterone Free/Total Dihydrotestosterone (DHT) Estrone Sulfate Estradiol Total Estrogens Progesterone Prolactin Thyroid - TSH, Others HbA1-C IGF-1 Fasting insulin C-reactive protein (CRP) Homocysteine Urine Deoxypyridinoline (DpD) Urine Pyridinium Crosslinks Carcinoembryonic Antigen (CEA) Luteinizing hormone (LH) Galectin-3 Other testing: 24 hour urine hormone evaluation with estrogen metabolites Heavy metal urine challenge test

13 Immune CBC with Differential IL-2 IL-6 IL-8 NK Cells

14 Metabolic IGF-1 Insulin HbA1C Cortisol Thyroid Panel Urine DpD Melatonin Others

15 Imaging: General & Cancer Specific MRI MRI-S PET vs CT Color Doppler Ultrasound Prostascint Scan Bone Scan

16 Approaches & Strategies Prevention of Metastasis & Angiogenesis Immune Enhancement Hormonal & Metabolic Modulation Direct Cytotoxicity Antioxidants, Anti Inflammatory & Anti Microbial Detoxification Circulation & Hyper Viscosity Improvement Redifferentiation

17 PREVENTION OF METASTASIS AND ANGIOGENESIS WITH MODIFIED CITRUS PECTIN

18 MODIFIED CITRUS PECTIN PROSTATE CANCER RESEARCH Published Clinical and Preclinical Data

19 Inhibition of Spontaneous Metastasis in a Rat Prostate Model by Oral Administration of Modified Citrus Pectin Pienta KJ, Naik H, Akhtar A, Yamazaki K, Replogle, TS, Lehr J, Donat TL, Tait L, Hogan V, Raz A Wayne State University School of Medicine, Detroit, MI, USA J Natl Cancer Inst (5): Method: MCPs inhibition of prostate cell adhesion to endothelial cells. 0.1% and 1.0% MCP in rats drinking water; controls had plain water Results: Significant reduction in lung metastases -- 50% reduction in 0.1% group; 56% reduction in 1.0% group (P<0.03 & P<0.001). Conclusion: MCP acted as potent inhibitor of spontaneous prostate carcinoma metastasis.

20 Effect of Modified Citrus Pectin on PSA Doubling Time in Prostate Cancer Patients: A Pilot Clinical Trial Method: MCP 15 g/day to patients with biochemical relapse post local therapy. PSA Doubling Time (PSADT) evaluated at intervals. Results: MCP significantly increased PSADT in prostate cancer patients. Strum S, Scholz M, McDermed J, McCulloch M, Eliaz, I Prostate Oncology Specialist, Marina del Rey, CA, USA Amitabha Medical Clinic & Healing Center, Sebastopol, CA, USA EcoNugenics, Santa Rosa, CA, USA. International Conference on Diet & The Prevention of Cancer 1999, Tampere, Finland.

21 Patient MCP Use (Months) PSADT ChangeStatus Patient % Response Patient % Response Patient 3 380% Response Patient 4>1555% Response Patient 5 66% P. Response Patient 6 6-7% Stable Disease Patient % No Response Pilot Clinical Results: MCPs Effect on PSA Doubling Time

22 Modified Citrus Pectin Increases the Prostate-Specific Antigen Doubling Time in Men with Prostate Cancer: A Phase II Pilot Study Guess BW, Scholz MC, Strum SB, Lam RY, Johnson HJ, Jennrich RI Healing Touch Oncology, Marina del Rey, CA, USA Prostate Cancer & Prostatic Disease 2003;6(4): Method: 10 men with biochemical prostate cancer relapse used MCP: 15g daily for 1 year. Results: MCP significantly increased PSADT in 7 out of the 10 participants (p<0.01).

23 968 % * * Phase II Study: PSADT Results After 1 Year

24 Using Splines to Detect Changes in PSA Doubling Times Guess B, Jennrich R, Johnson H, Redheffer R, Scholz M, Healing Touch Oncology, Marin del Ray, CA, Department of Statistics, UCLA, CA, The Prostate :88-95.

25 MCP Typical Patient Results

26 Clinical Benefit in Patients with Advanced Solid Tumors Treated with Modified Citrus Pectin Azémar M, Hildenbrand B, Haering B, Heim ME, Unger C, Albert-Ludwigs-University in Freiburg, Germany, Sonnenberg-Klinik, Bad Sooden-Allendorf, Germany Method: MCP 15g daily. Results: 49 patients with advanced solid tumors. 29 evaluated after 2 months -- 21% showed stabilization & improvements in quality of life. One patient w/ metastasized prostate carcinoma showed 50% decrease in PSA, with significant increase in quality of life & decrease in pain. Conclusion: MCP shows clinical benefits & improvements in quality of life in advanced cancer patients.

27 IMMUNE ENHANCEMENT IN PROSTATE CANCER TREATMENT

28 Immune Enhancement Medicinal Mushrooms Modified Citrus Pectin Honokiol Botanicals - Astragalus, Eleutherococcus, Others BCG (Bacillus Calmette-Guérin) Vaccine

29 DIRECT CYTOTOXICITY

30 Direct Cytotoxicity in Prostate Cancer Treatment Curcumin, Green Tea Extracts Ban Zhi Lian (Scutellariae barbata) Artemisinin MCP Honokiol MCP + Honokiol Others

31 Effect of Honokiol on Growth of PC3 Cells (Pre-Published data)

32 Synergistic Effect of MCP & Honokiol on PC3 Cell Line Migration (Pre-Published Data)

33 BA Poly Botanical & MCP Effect on Migration of Human Prostate Cancer Cells The invasive behavior of PC3 evaluated using migration assay in the presence of (A) MCP (mg/mL) & (B) MCP (mg/mL) plus Poly Botanical (10 ug/mL). Poly Botanical

34 CIRCULATION AND HYPERVISCOSITY IMPROVEMENT IN PROSTATE CANCER TREATMENT

35 Medications, Supplements & Approaches Aspirin Clopidogrel LMW Heparin Nattokinase Lumbrokinase Botanicals Exercise

36 Redifferentiation Vitamin D3 Sodium Phenyl Butyrate (SPB) Honokiol


Download ppt "INTEGRATIVE APPROACHES TO TREATING PROSTATE CANCER AND PROSTATITIS."

Similar presentations


Ads by Google